Leading laboratory, diagnostics, and tools companies spent more than $26 million on Washington, D.C. lobbying in the first half of 2026, according to reporting that points to reimbursement and coverage issues for laboratory testing as a major focus. Stakeholders also emphasized federal funding for scientific research and policy changes tied to PAMA (Protecting Access to Medicare Act). The filings indicate sustained industry involvement in shaping reimbursement pathways that affect diagnostic adoption and downstream clinical utilization. For biotech and diagnostics firms, these policy levers can influence pricing models and the speed at which new tests move into routine care. The report provides a snapshot of where industry attention is concentrated as regulators and payers weigh coverage and payment structures for diagnostics.